Estimates vary, but around 5–15% of all patients with pancreatic cancer have a detectable pathogenic DDR-related gene variant, and around 5% have a BRCA1/2 variant specifically [14–16]. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.